Logo image
ADVERSE EVENTS IN PATIENTS WITH LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS <25 OR <15 MG/DL ON AT LEAST TWO CONSECUTIVE VISITS IN FOURTEEN RANDOMIZED, CONTROLLED, CLINICAL TRIALS OF ALIROCUMAB
Abstract   Open access   Peer reviewed

ADVERSE EVENTS IN PATIENTS WITH LOW-DENSITY LIPOPROTEIN CHOLESTEROL LEVELS <25 OR <15 MG/DL ON AT LEAST TWO CONSECUTIVE VISITS IN FOURTEEN RANDOMIZED, CONTROLLED, CLINICAL TRIALS OF ALIROCUMAB

Jennifer Robinson, Michel Farnier, Umesh Chaudhari, Bill Sasiela, Christelle Lorenzato, Kathryn Miller and John Kastelein
Journal of the American College of Cardiology, Vol.65(10), pp.A1350-A1350
03/17/2015
DOI: 10.1016/S0735-1097(15)61350-X
url
https://doi.org/10.1016/s0735-1097(15)61350-xView
Published (Version of record) Open Access

Abstract

Consequences of very low LDL-C levels are not well understood. [...]AE rates were examined in patients (pts) who achieved 2 consecutive calculated LDL-C <25 or <15 mg/dL on alirocumab (ALI).
Cholesterol Diabetes Infections Laboratories Low density lipoprotein Pain

Details

Logo image